DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

Histopathology

Volumn 57, Issue 2, 2010, Pages 259-270

  Novelli, Marco ^a   Rossi, Sabrina ^b   Rodriguez Justo, Manuel ^a   Taniere, Philippe ^c   Seddon, Beatrice ^a   Toffolatti, Luisa ^b   Sartor, Chiara ^b   Hogendoorn, Pancras C W ^d   Sciot, Raf ^e   Van Glabbeke, Martine ^f   Verweij, Jaap ^g   Blay, Jean Yves ^h   Hohenberger, Peter ⁱ   Flanagan, Adrienne ^a   Dei Tos, Angelo P ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b General Hospital of Treviso   (Italy)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d Department of Pathology   (Netherlands)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f EORTC DATA CENTER   (Belgium)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h CENTRE LÉON BÉRARD   (France)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD117; DOG1; GIST; immunodiagnosis

Indexed keywords

CD34 ANTIBODY; CD34 ANTIGEN; DESMIN; DOG1 ANTIBODY; DOG1 PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NESTIN; PROTEIN KINASE C THETA; PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EXON; FIBROMATOSIS; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GRANULAR CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; NEURILEMOMA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SPINDLE CELL CARCINOMA; TISSUE MICROARRAY;

ANTIBODIES; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-KIT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955817308     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03624.x     Document Type: Article

References (34)

1. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 279 577 580. (Pubitemid 28067289)
2. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int. J. Surg. Pathol. 2002 10 81 89. (Pubitemid 34655094)
3. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J. Pathol. 2004 202 430 438.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006 130 1466 1478.
5. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am. J. Surg. Pathol. 2009 33 437 446.
6. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 299 708 710.
7. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 2006 42 1093 1103.
8. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008 26 5352 5359.
9. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 2008 26 626 632.
10. Agaram NP, Laquaglia MP, Ustun B et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 2008 14 3204 3215.
11. Sciot R, Debiec-Rychter M, Daugaard S et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur. J. Cancer 2008 44 1855 1860.
12. Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J et al. Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am. J. Pathol. 2001 158 817 823.
13. Yi ES, Strong CR, Piao Z, Perucho M, Weidner N. Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity. Appl. Immunohistochem. Mol. Morphol. 2005 13 157 161.
14. Kaifi JT, Strelow A, Schurr PG et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod. Pathol. 2006 19 399 406.
15. West RB, Corless CL, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 2004 165 107 113.
16. Blay P, Astudillo A, Buesa JM et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin. Cancer Res. 2004 10 4089 4095.
17. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004 364 1127 1134.
18. Romeo S, Debiec-Rychter M, Van Glabbeke M et al. Cell cycleapoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin. Cancer Res. 2009 15 4191 4198.
19. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009 373 1097 1104.
20. Parfitt JR, Rodriguez-Justo M, Feakins R, Novelli MR. Gastrointestinal Kaposi's sarcoma: CD117 expression and the potential for misdiagnosis as gastrointestinal stromal tumour. Histopathology 2008 52 816 823.
21. Seya T, Tanaka N, Shinji S et al. Case of rectal malignant melanoma showing immunohistochemical variability in a tumor. J. Nippon Med. Sch. 2007 74 377 381.
22. Rossi G, Valli R, Bertolini F et al. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology 2005 46 522 531.
23. Peterson MR, Piao Z, Weidner N, Yi ES. Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl. Immunohistochem. Mol. Morphol. 2006 14 390 396.
24. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004 28 889 894.
25. Sarlomo-Rikala M, Tsujimura T, Lendahl U, Miettinen M. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 2002 110 499 507.
26. Espinosa I, Lee CH, Kim MK et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2008 32 210 218.
27. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am. J. Surg. Pathol. 2009 33 1401 1408.
28. Lee HE, Kim MA, Lee HS, Lee BL, Kim WH. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J. Clin. Pathol. 2008 61 722 729.
29. Hou YY, Tan YS, Xu JF et al. Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology 2006 48 536 545.
30. Steigen SE, Bjerkehagen B, Haugland HK et al. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod. Pathol. 2008 21 46 53.
31. Sirgi KE, Wick MR, Swanson PE. B72.3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumors. Adjuncts in the recognition of endothelial neoplasms. Am. J. Surg. Pathol. 1993 17 179 185.
32. Fisher C, Goldblum JR, Epstein JI, Montgomery E. Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am. J. Surg. Pathol. 2001 25 1143 1149.
33. Parfitt JR, Streutker CJ, Riddell RH, Driman DK. Gastrointestinal stromal tumors: a contemporary review. Pathol. Res. Pract. 2006 202 837 847.
34. Antonescu CR, Viale A, Sarran L et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin. Cancer Res. 2004 10 3282 3290.